12:00 AM
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IMO-3100: Phase IIa data

Top-line data from a double-blind, U.S. Phase IIa trial in 44 patients with moderate to severe plaque psoriasis showed that once-weekly subcutaneous IMO-3100 for 4 weeks with a 4 week follow-up period missed the primary endpoint of reducing median epidermal thickness at week 8 as measured by skin biopsies vs. placebo (6.4% vs. an increase of 7.7%, p-value not disclosed). According to Idera, a known limitation of skin biopsies after 4 weeks of...

Read the full 344 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >